Suppr超能文献

结核病中的皮质类固醇。

Corticosteroids in tuberculosis.

作者信息

Cisneros J R, Murray K M

机构信息

Department of Pharmaceutical Services, Morton Plant Mease Healthcare, Clearwater, FL 34617, USA.

出版信息

Ann Pharmacother. 1996 Nov;30(11):1298-303. doi: 10.1177/106002809603001115.

Abstract

OBJECTIVE

To examine the effects of corticosteroids used for concomitant disease states in patients with latent or active tuberculosis (TB). The role of corticosteroids in the treatment of extrapulmonary TB is also discussed.

DATA SOURCES

A MEDLINE search was conducted for the years 1953-1995. The International Pharmaceutical Abstracts service was also used to conduct an extensive literature review. In addition, relevant articles were cross-referenced to screen for additional information.

STUDY SELECTION/DATA EXTRACTION: During the literature review, emphasis was placed on human studies and individual case reports.

DATA SYNTHESIS

The resurgence of TB in this decade has affected many populations, especially immunocompromised patients. These patients may need corticosteroid therapy for various concomitant diseases that might predispose a patient to develop primary TB infection or reactivate latent TB infection. In appropriate patients, prophylaxis with isoniazid is recommended. Corticosteroid therapy may benefit patients with some forms of extrapulmonary TB. After steroid therapy, improved survival and more rapid reduction of tuberculous symptoms have been noted in cases of tuberculous pleurisy, endobronchial TB, tuberculous meningitis, and tuberculous pericarditis. Corticosteroids may also be useful in controlling both fever and hypersensitivity reactions in pulmonary and extrapulmonary TB, although not routinely used for this purpose.

CONCLUSIONS

Corticosteroids may play an important role in TB infection by promoting reactivation of latent infection. Corticosteroids may modify symptoms of some forms of extrapulmonary TB, although randomized, placebo-controlled studies are needed before corticosteroids will have a definitive place in the standard therapy of TB.

摘要

目的

研究皮质类固醇用于潜伏性或活动性结核病(TB)患者合并疾病状态时的效果。还讨论了皮质类固醇在肺外结核病治疗中的作用。

数据来源

对1953年至1995年期间进行了MEDLINE检索。还利用国际药学文摘服务进行了广泛的文献综述。此外,对相关文章进行交叉引用以筛选更多信息。

研究选择/数据提取:在文献综述过程中,重点关注人体研究和个案报告。

数据综合

本十年结核病的再度流行影响了许多人群,尤其是免疫功能低下的患者。这些患者可能因各种合并疾病而需要皮质类固醇治疗,这些合并疾病可能使患者易患原发性结核感染或使潜伏性结核感染重新激活。对于合适的患者,建议使用异烟肼进行预防。皮质类固醇治疗可能对某些形式的肺外结核病患者有益。在类固醇治疗后,结核性胸膜炎、支气管内膜结核、结核性脑膜炎和结核性心包炎患者的生存率提高,结核症状更快减轻。皮质类固醇在控制肺结核和肺外结核的发热和过敏反应方面也可能有用,尽管通常不为此目的使用。

结论

皮质类固醇可能通过促进潜伏感染的重新激活在结核感染中发挥重要作用。皮质类固醇可能会改善某些形式的肺外结核病的症状,不过在皮质类固醇在结核病标准治疗中占据明确地位之前,还需要进行随机、安慰剂对照研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验